l carnitine and amlodipine Myvitamins L-Carnitine Tablets | Performance L-Carnitine 500mg | 60 Capsules

doi: 10.1186/s12931-024-02677-6 120

Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Active Links 239000007924 injection Substances 0.000 title claims abstract description 103 238000002347 injection Methods 0.000 title claims abstract description 103 RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 title claims abstract description 102 108010024636 Glutathione Proteins 0.000 title claims abstract description 83 238000002360 preparation method Methods 0.000 title claims abstract description 32 HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 84 239000000243 solution Substances 0.000 claims abstract description 79 XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 43 IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 33 QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 30 239000001301 oxygen Substances 0.000 claims abstract description 30 229910052760 oxygen Inorganic materials 0.000 claims abstract description 30 239000008215 water for injection Substances 0.000 claims abstract description 27 239000007788 liquid Substances 0.000 claims abstract description 25 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 14 238000005429 filling process Methods 0.000 claims abstract description 11 238000011049 filling Methods 0.000 claims description 34 238000000034 method Methods 0.000 claims description 26 238000004108 freeze drying Methods 0.000 claims description 24 238000003756 stirring Methods 0.000 claims description 23 239000003814 drug Substances 0.000 claims description 19 230000008569 process Effects 0.000 claims description 18 229940079593 drug Drugs 0.000 claims description 15 OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 14 229910052799 carbon Inorganic materials 0.000 claims description 14 238000001914 filtration Methods 0.000 claims description 14 229960003180 glutathione Drugs 0.000 claims description 12 238000004519 manufacturing process Methods 0.000 claims description 12 238000010438 heat treatment Methods 0.000 claims description 10 239000005388 borosilicate glass Substances 0.000 claims description 8 238000001816 cooling Methods 0.000 claims description 7 239000012528 membrane Substances 0.000 claims description 7 239000012982 microporous membrane Substances 0.000 claims description 7 238000005192 partition Methods 0.000 claims description 7 238000005096 rolling process Methods 0.000 claims description 7 238000005303 weighing Methods 0.000 claims description 7 229910001873 dinitrogen Inorganic materials 0.000 claims description 5 230000008901 benefit Effects 0.000 abstract description 4 229940090044 injection Drugs 0.000 description 82 239000000047 product Substances 0.000 description 69 239000012535 impurity Substances 0.000 description 24 238000012360 testing method Methods 0.000 description 22 239000000843 powder Substances 0.000 description 9 239000000126 substance Substances 0.000 description 9 238000012795 verification Methods 0.000 description 9 241000283973 Oryctolagus cuniculus Species 0.000 description 7 WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6 238000001514 detection method Methods 0.000 description 6 238000001035 drying Methods 0.000 description 6 229940093181 glucose injection Drugs 0.000 description 6 230000007794 irritation Effects 0.000 description 6 125000003396 thiol group Chemical group [H]S* 0.000 description 6 238000006243 chemical reaction Methods 0.000 description 5 230000006378 damage Effects 0.000 description 5 230000017074 necrotic cell death Effects 0.000 description 5 230000000638 stimulation Effects 0.000 description 5 206010002198 Anaphylactic reaction Diseases 0.000 description 4 208000003455 anaphylaxis Diseases 0.000 description 4 210000004027 cell Anatomy 0.000 description 4 230000000052 comparative effect Effects 0.000 description 4 238000007918 intramuscular administration Methods 0.000 description 4 210000003205 muscle Anatomy 0.000 description 4 238000011020 pilot scale process Methods 0.000 description 4 230000008859 change Effects 0.000 description 3 230000003412 degenerative effect Effects 0.000 description 3 239000012467 final product Substances 0.000 description 3 238000001727 in vivo Methods 0.000 description 3 238000011835 investigation Methods 0.000 description 3 239000000463 material Substances 0.000 description 3 210000000056 organ Anatomy 0.000 description 3 230000003647 oxidation Effects 0.000 description 3 238000007254 oxidation reaction Methods 0.000 description 3 239000002245 particle Substances 0.000 description 3 230000001575 pathological effect Effects 0.000 description 3 239000002994 raw material Substances 0.000 description 3 239000008354 sodium chloride injection Substances 0.000 description 3 PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 3 230000002792 vascular Effects 0.000 description 3 241000700198 Cavia Species 0.000 description 2 241000700199 Cavia porcellus Species 0.000 description 2 102000004190 Enzymes Human genes 0.000 description 2 108090000790 Enzymes Proteins 0.000 description 2 108010053070 Glutathione Disulfide Proteins 0.000 description 2 DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2 240000007711 Peperomia pellucida Species 0.000 description 2 239000003963 antioxidant agent Substances 0.000 description 2 230000003078 antioxidant effect Effects 0.000 description 2 239000005515 coenzyme Substances 0.000 description 2 230000007850 degeneration Effects 0.000 description 2 230000000694 effects Effects 0.000 description 2 239000002158 endotoxin Substances 0.000 description 2 238000002474 experimental method Methods 0.000 description 2 YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 2 230000002949 hemolytic effect Effects 0.000 description 2 230000036512 infertility Effects 0.000 description 2 230000008595 infiltration Effects 0.000 description 2 238000001764 infiltration Methods 0.000 description 2 210000004969 inflammatory cell Anatomy 0.000 description 2 238000010255 intramuscular injection Methods 0.000 description 2 239000007927 intramuscular injection Substances 0.000 description 2 238000010606 normalization Methods 0.000 description 2 YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 2 238000011076 safety test Methods 0.000 description 2 239000002904 solvent Substances 0.000 description 2 230000008961 swelling Effects 0.000 description 2 YPZRWBKMTBYPTK-USZNOCQGSA-N (2r)-2-amino-5-[[(2r)-3-[[(2r)-2-[[(4s)-4-amino-4-carboxybutanoyl]amino]-3-(carboxymethylamino)-3-oxopropyl]disulfanyl]-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@@H](N)C(O)=O YPZRWBKMTBYPTK-USZNOCQGSA-N 0.000 description 1 XUKUURHRXDUEBC-SXOMAYOGSA-N (3s,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SXOMAYOGSA-N 0.000 description 1 AAEQXEDPVFIFDK-UHFFFAOYSA-N 3-(4-fluorobenzoyl)-2-(2-methylpropanoyl)-n,3-diphenyloxirane-2-carboxamide Chemical compound C=1C=CC=CC=1NC(=O)C1(C(=O)C(C)C)OC1(C=1C=CC=CC=1)C(=O)C1=CC=C(F)C=C1 AAEQXEDPVFIFDK-UHFFFAOYSA-N 0.000 description 1 ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1 101710088194 Dehydrogenase Proteins 0.000 description 1 201000004624 Dermatitis Diseases 0.000 description 1 BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1 WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1 239000004471 Glycine Substances 0.000 description 1 229930189936 Glyoxalase Natural products 0.000 description 1 206010018910 Haemolysis Diseases 0.000 description 1 208000032843 Hemorrhage Diseases 0.000 description 1 206010020565 Hyperaemia Diseases 0.000 description 1 206010021143 Hypoxia Diseases 0.000 description 1 206010061218 Inflammation Diseases 0.000 description 1 XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1 ZUKPVRWZDMRIEO-VKHMYHEASA-N L-cysteinylglycine Chemical compound SC[C@H]([NH3+])C(=O)NCC([O-])=O ZUKPVRWZDMRIEO-VKHMYHEASA-N 0.000 description 1 WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1 241001465754 Metazoa Species 0.000 description 1 238000002835 absorbance Methods 0.000 description 1 239000002253 acid Substances 0.000 description 1 238000009098 adjuvant therapy Methods 0.000 description 1 238000005054 agglomeration Methods 0.000 description 1 230000002776 aggregation Effects 0.000 description 1 230000036783 anaphylactic response Effects 0.000 description 1 208000007502 anemia Diseases 0.000 description 1 238000010923 batch production Methods 0.000 description 1 238000005842 biochemical reaction Methods 0.000 description 1 230000008827 biological function Effects 0.000 description 1 230000031709 bromination Effects 0.000 description 1 238000005893 bromination reaction Methods 0.000 description 1 150000001720 carbohydrates Chemical class 0.000 description 1 235000014633 carbohydrates Nutrition 0.000 description 1 230000005779 cell damage Effects 0.000 description 1 208000037887 cell injury Diseases 0.000 description 1 210000000170 cell membrane Anatomy 0.000 description 1 239000003795 chemical substances by application Substances 0.000 description 1 230000007012 clinical effect Effects 0.000 description 1 239000013065 commercial product Substances 0.000 description 1 239000013078 crystal Substances 0.000 description 1 XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1 235000018417 cysteine Nutrition 0.000 description 1 206010012601 diabetes mellitus Diseases 0.000 description 1 238000010790 dilution Methods 0.000 description 1 239000012895 dilution Substances 0.000 description 1 201000010099 disease Diseases 0.000 description 1 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1 230000037149 energy metabolism Effects 0.000 description 1 230000002255 enzymatic effect Effects 0.000 description 1 210000003743 erythrocyte Anatomy 0.000 description 1 230000029142 excretion Effects 0.000 description 1 235000019197 fats Nutrition 0.000 description 1 238000007710 freezing Methods 0.000 description 1 230000008014 freezing Effects 0.000 description 1 125000000524 functional group Chemical group 0.000 description 1 235000013922 glutamic acid Nutrition 0.000 description 1 239000004220 glutamic acid Substances 0.000 description 1 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1 229920005555 halobutyl Polymers 0.000 description 1 230000008588 hemolysis Effects 0.000 description 1 210000005260 human cell Anatomy 0.000 description 1 208000018875 hypoxemia Diseases 0.000 description 1 230000002779 inactivation Effects 0.000 description 1 238000009776 industrial production Methods 0.000 description 1 230000004054 inflammatory process Effects 0.000 description 1 230000003834 intracellular effect Effects 0.000 description 1 238000001990 intravenous administration Methods 0.000 description 1 238000010253 intravenous injection Methods 0.000 description 1 210000003734 kidney Anatomy 0.000 description 1 238000011031 large-scale manufacturing process Methods 0.000 description 1 210000004185 liver Anatomy 0.000 description 1 238000011068 loading method Methods 0.000 description 1 238000007726 management method Methods 0.000 description 1 230000004060 metabolic process Effects 0.000 description 1 239000002207 metabolite Substances 0.000 description 1 QLTHBWIACSBXPR-UHFFFAOYSA-N methyl 3-isocyanatopropanoate Chemical compound COC(=O)CCN=C=O QLTHBWIACSBXPR-UHFFFAOYSA-N 0.000 description 1 244000005700 microbiome Species 0.000 description 1 230000033116 oxidation-reduction process Effects 0.000 description 1 239000000825 pharmaceutical preparation Substances 0.000 description 1 239000004033 plastic Substances 0.000 description 1 231100000572 poisoning Toxicity 0.000 description 1 230000000607 poisoning effect Effects 0.000 description 1 230000001737 promoting effect Effects 0.000 description 1 230000022558 protein metabolic process Effects 0.000 description 1 230000008439 repair process Effects 0.000 description 1 238000011160 research Methods 0.000 description 1 230000002441 reversible effect Effects 0.000 description 1 238000010181 skin prick test Methods 0.000 description 1 230000009885 systemic effect Effects 0.000 description 1 238000010257 thawing Methods 0.000 description 1 210000001519 tissue Anatomy 0.000 description 1 230000004102 tricarboxylic acid cycle Effects 0.000 description 1 150000003641 trioses Chemical class 0.000 description 1 210000003462 vein Anatomy 0.000 description 1 230000004580 weight loss Effects 0.000 description 1 Classifications AHUMAN NECESSITIES A61MEDICAL OR VETERINARY SCIENCE

Vascular damage in a mouse model of diabetic retinopathy: relation to neuronal and glial changes

A deep understanding of these effects and their mechanisms is crucial for optimizing MSC-based regenerative therapy strategies for the intervertebral disc